Volume 16, Issue 3 (7-2026)                   J Adv Biomed Sci. 2026, 16(3): 251-264 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Keshtmand M, Sadeghi M. Identification of Alkaloid-Derived α-Glucosidase Inhibitors for Diabetes Management: An In Silico Approach. J Adv Biomed Sci. 2026; 16 (3) :251-264
URL: http://jabs.fums.ac.ir/article-1-3216-en.html
1- Department of Biochemistry, Sa.C., Islamic Azad University, Sanandaj, Iran
2- Department of Biochemistry, Sa.C., Islamic Azad University, Sanandaj, Iran , ms.biochemistry2015@gmail.com
Abstract:   (80 Views)
Background & Objectives: Alkaloids constitute a structurally diverse class of naturally occurring compounds with a wide range of pharmacological activities. One of the principal mechanisms through which alkaloids may contribute to the management of diabetes mellitus (DM) is the inhibition of α-glucosidase. Despite their considerable therapeutic potential, the molecular interactions between alkaloids and α-glucosidase remain insufficiently characterized and warrant comprehensive investigation. Therefore, this study aimed to identify potential alkaloid-derived α-glucosidase inhibitors using an in silico approach for the management of DM.
Materials & Methods: An initial computational screening of 15 alkaloid ligands excluded cepharanthine because of predicted mutagenicity and immunotoxicity, whereas tetrandrine and fangchinoline were excluded because they failed to satisfy drug-likeness criteria. The remaining 12 compounds were subsequently subjected to molecular docking against α-glucosidase.
Results: Scopolamine exhibited the most favorable docking score (-6.91 kcal/mol), outperforming acarbose, the reference inhibitor (-6.87 kcal/mol). In the α-glucosidase and scopolamine complex, Arg699 and Glu301 participated in hydrogen bond and Pi anion interactions, respectively. Secondary structure analysis further revealed scopolamine induced conformational alterations in α-glucosidase, characterized by an increase in α-helix content and a reduction in β-sheet content, changes that were consistent with its predicted inhibitory activity.
Conclusion: These findings suggest that scopolamine is a promising candidate α-glucosidase inhibitor. Nevertheless, further in vitro and in vivo studies are required to validate its antidiabetic potential and determine its therapeutic value for controlling postprandial hyperglycemia in DM.
Full-Text [PDF 2669 kb]   (26 Downloads)    
Type of Study: Research | Subject: Biochemistry
Received: 2026/01/29 | Revised: 2026/07/29 | Accepted: 2026/07/14 | Published: 2026/07/1

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Journal of Advanced Biomedical Sciences

Designed & Developed by: Yektaweb

Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)